Literature DB >> 8406894

Effect of orally administered monoclonal antibody on persistent Cryptosporidium parvum infection in scid mice.

L E Perryman1, K A Kegerris, P H Mason.   

Abstract

Scid mice, persistently infected after exposure to 10(7) Cryptosporidium parvum oocysts, were treated daily for 14 to 17 days with 0.4 mg of monoclonal antibody (mAb) 17.41 administered by the oral route. Mice receiving mAb 17.41 shed significantly fewer (P < 0.005) C. parvum oocysts than scid mice receiving isotype control mAb. Intestinal (but not gastric) infectivity scores were also reduced for scid mice treated with mAb 17.41 (P < 0.01).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8406894      PMCID: PMC281254          DOI: 10.1128/iai.61.11.4906-4908.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  Isolated antral narrowing associated with gastrointestinal cryptosporidiosis in acquired immunodeficiency syndrome.

Authors:  E Cersosimo; C J Wilkowske; J E Rosenblatt; J Ludwig
Journal:  Mayo Clin Proc       Date:  1992-06       Impact factor: 7.616

2.  Cryptosporidiosis in adult and neonatal mice with severe combined immunodeficiency.

Authors:  T L Kuhls; R A Greenfield; D A Mosier; D L Crawford; W A Joyce
Journal:  J Comp Pathol       Date:  1992-05       Impact factor: 1.311

Review 3.  Cryptosporidium species, a protean protozoan.

Authors:  E N Janoff; L B Reller
Journal:  J Clin Microbiol       Date:  1987-06       Impact factor: 5.948

Review 4.  Cryptosporidium spp. and cryptosporidiosis.

Authors:  R Fayer; B L Ungar
Journal:  Microbiol Rev       Date:  1986-12

Review 5.  Cryptosporidiosis: clinical, epidemiologic, and parasitologic review.

Authors:  T R Navin; D D Juranek
Journal:  Rev Infect Dis       Date:  1984 May-Jun

Review 6.  Cryptosporidium and cryptosporidiosis.

Authors:  R Soave; D Armstrong
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

7.  Human cryptosporidiosis in the acquired immune deficiency syndrome.

Authors:  L A Guarda; S A Stein; K A Cleary; N G Ordóñez
Journal:  Arch Pathol Lab Med       Date:  1983-11       Impact factor: 5.534

8.  Human cryptosporidiosis in immunocompetent and immunodeficient persons. Studies of an outbreak and experimental transmission.

Authors:  W L Current; N C Reese; J V Ernst; W S Bailey; M B Heyman; W M Weinstein
Journal:  N Engl J Med       Date:  1983-05-26       Impact factor: 91.245

9.  Cryptosporidiosis of the stomach and small intestine in patients with AIDS.

Authors:  R N Berk; S D Wall; C B McArdle; J A McCutchan; A R Clemett; J S Rosenblum; A Premkumer; A J Megibow
Journal:  AJR Am J Roentgenol       Date:  1984-09       Impact factor: 3.959

Review 10.  Autopsy pathology in the acquired immune deficiency syndrome.

Authors:  C M Reichert; T J O'Leary; D L Levens; C R Simrell; A M Macher
Journal:  Am J Pathol       Date:  1983-09       Impact factor: 4.307

View more
  11 in total

1.  Enteral human serum immunoglobulin treatment of cryptosporidiosis in mice with severe combined immunodeficiency.

Authors:  T L Kuhls; S L Orlicek; D A Mosier; D L Crawford; V L Abrams; R A Greenfield
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

Review 2.  SCID mice and the study of parasitic disease.

Authors:  K B Seydel; S L Stanley
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

3.  Cloning and sequence analysis of a highly polymorphic Cryptosporidium parvum gene encoding a 60-kilodalton glycoprotein and characterization of its 15- and 45-kilodalton zoite surface antigen products.

Authors:  W B Strong; J Gut; R G Nelson
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

4.  Efficacy of monoclonal antibodies against defined antigens for passive immunotherapy of chronic gastrointestinal cryptosporidiosis.

Authors:  Michael W Riggs; Deborah A Schaefer; Sushila J Kapil; Lise Barley-Maloney; Lance E Perryman
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

5.  In vitro inhibition of Cryptosporidium parvum infection by human monoclonal antibodies.

Authors:  B C Elliot; A V Wisnewski; J Johnson; D Fenwick-Smith; P Wiest; D Hamer; T Kresina; T P Flanigan
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

6.  Comparison of Cryptosporidium parvum and Cryptosporidium wrairi by reactivity with monoclonal antibodies and ability to infect severe combined immunodeficient mice.

Authors:  C E Chrisp; P Mason; L E Perryman
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

7.  Infection dynamics and clinical features of cryptosporidiosis in SCID mice.

Authors:  J R Mead; N Ilksoy; X You; Y Belenkaya; M J Arrowood; M T Fallon; R F Schinazi
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

8.  Effect of spleen cell populations on resolution of Cryptosporidium parvum infection in SCID mice.

Authors:  L E Perryman; P H Mason; C E Chrisp
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

9.  Concurrent response to challenge infection with Cryptosporidium parvum in immunosuppressed C57BL/6N mice.

Authors:  Chan-Gu Surl; Hyeon-Cheol Kim
Journal:  J Vet Sci       Date:  2006-03       Impact factor: 1.672

Review 10.  Immunoglobulin Y for Potential Diagnostic and Therapeutic Applications in Infectious Diseases.

Authors:  Lucia Lee; Kate Samardzic; Michael Wallach; Lyn R Frumkin; Daria Mochly-Rosen
Journal:  Front Immunol       Date:  2021-06-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.